

# Ajay Dhakal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4856510/publications.pdf>

Version: 2024-02-01

23  
papers

113  
citations

1478505

6  
h-index

1281871

11  
g-index

23  
all docs

23  
docs citations

23  
times ranked

214  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P4-06-07: Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA). Cancer Research, 2022, 82, P4-06-07-P4-06-07.	0.9	0
2	Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?. Cancers, 2022, 14, 1856.	3.7	12
3	Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. Breast Disease, 2022, 41, 255-260.	0.8	2
4	Significance of HER2 in Microinvasive Breast Carcinoma. American Journal of Clinical Pathology, 2021, 156, 155-165.	0.7	9
5	Adjuvant cyclinâ€dependent kinase 4/6 inhibition in hormone receptorâ€positive breast cancer: One Monarch to rule them all?. Cancer, 2021, 127, 3302-3309.	4.1	3
6	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 11878.	4.1	1
7	Leptomeningeal Disease as an Initial Presenting Manifestation in Breast Cancer. Cureus, 2021, 13, e19666.	0.5	0
8	Neratinib-Induced Duodenal Ulcer: A Case Report. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342093587.	1.1	1
9	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342094486.	1.1	20
10	Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptorâ€Positive Breast Cancer. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342097638.	1.1	3
11	Efficacy of Palbociclib Combinations in Hormone Receptorâ€Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. Clinical Breast Cancer, 2018, 18, e1401-e1405.	2.4	24
12	Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature. Case Reports in Medicine, 2018, 2018, 1-5.	0.7	16
13	Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.. Journal of Clinical Oncology, 2018, 36, 1064-1064.	1.6	14
14	A 51-Year-Old Woman With an Increasing Chest Wall Mass Years After Resection of an Early Stage Lung Cancer. Chest, 2017, 152, e151-e154.	0.8	0
15	Outcome of palbociclib based therapy in hormone receptor positive metastatic breast cancer patients after treatment with everolimus.. Journal of Clinical Oncology, 2017, 35, 1054-1054.	1.6	2
16	Abstract 5709: Variation in Merlin expression and its prognostic significance in malignant pleural mesothelioma. , 2017, , .		0
17	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer. Novel Approaches in Cancer Study, 2017, 1, .	0.2	0
18	Comparing the Outcome of Diffuse Large B-Cell Lymphoma in Very Elderly Patients (age greater than 80) Tj ETQq0 0.0 rgBT /Qoverlock 10	1.4	0

#	ARTICLE	IF	CITATIONS
19	Bortezomib Induced Pulmonary Toxicity. Blood, 2014, 124, 5731-5731.	1.4	3
20	Diffuse Large B Cell Lymphoma in Very Elderly Patients. Blood, 2014, 124, 5453-5453.	1.4	0
21	Rituximab Monotherapy for Primary Cutaneous Follicle Center Lymphoma. Orthodontic Journal of Nepal, 2012, 1, 16-18.	0.1	0
22	Influence of duration of symptoms over perioperative outcomes during emergency laparoscopic cholecystectomy. Kathmandu University Medical Journal, 2010, 7, 120-124.	0.2	3
23	What about the government service?. Kathmandu University Medical Journal, 2008, 6, 291-3.	0.2	0